Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study)
NCT04216589 is a phase 2 interventional trial sponsored by National Institute of Allergy and Infectious Diseases (NIAID). As of 21 Nov 2026, it is completed. It studies Semaglutide in HIV Infections and Non-Alcoholic Fatty Liver Disease. The registry lists an enrollment of 51 participants at 9 sites in 2 countries. The registry lists a start date of 19 Feb 2021 and a primary completion date of 16 Mar 2023. 2 of its registered investigators have a FindMyKOL profile.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT04216589 |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional trial |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID) |
| Enrollment | 51 |
| Registered sites | 9 |
| Countries | 2 |
| Conditions | HIV Infections and Non-Alcoholic Fatty Liver Disease |
| Drugs | Semaglutide |
| Start | 19 Feb 2021 |
| Primary completion | 16 Mar 2023 |
| Study completion | 15 Sept 2023 |
| Last update posted | 1 Oct 2024 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
9 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Alabama Crs (site Id: 31788)
Birmingham
- University of Colorado Hospital Crs (site Id: 6101)
Aurora
- Johns Hopkins University Crs
Baltimore
- Massachusetts General Hospital Crs (mgh Crs) (site Id: 101)
Boston
- Cincinnati Clinical Research Site (site Id: 2401)
Cincinnati
- Ohio State University Crs (site Id: 2301)
Columbus
- Houston Aids Research Team Crs (site Id: 31473)
Houston
- University of Washington Aids Crs (site Id: 1401)
Seattle
- Instituto de Pesquisa Clinica Evandro Chagas (ipec) Crs (site Id: 12101)
Rio de Janeiro
United States, by state
Outside the United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT04216589
Each answer restates registry values shown on this page.
What is NCT04216589?
NCT04216589 is a phase 2 interventional trial sponsored by National Institute of Allergy and Infectious Diseases (NIAID). It studies Semaglutide in HIV Infections and Non-Alcoholic Fatty Liver Disease.
Who leads NCT04216589?
The registry names Jordan E. Lake, MD, MSc (study chair, Houston AIDS Research Team CRS) and Kristine Erlandson, MD, MS (study chair, University of Colorado Hospital CRS) as overall officials.
Where does NCT04216589 run?
The registry lists 9 sites in 2 countries. Most sites are in these countries: United States (8) and Brazil (1).
Which drugs does NCT04216589 study?
The registered drug and biological interventions are Semaglutide.
When did NCT04216589 end?
The registry lists a primary completion date of 16 Mar 2023 and a study completion date of 15 Sept 2023. The sponsor last updated the record on 1 Oct 2024.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.